Collaborative Care in Myelofibrosis is organized by Healio.
Release Date: October 25, 2023
Expiration Date: October 25, 2024
Activity Description:
Anemia occurs in nearly all patients with myelofibrosis and is associated with poor prognosis, worse survival, and reduced quality of life. Patients with anemia will often require blood transfusion, though a subset will derive temporary benefit from androgens, corticosteroids, immunomodulators, or erythropoiesis-stimulating agents. Since the majority of patients will not have a prolonged response to these agents, new therapies are needed and may soon enter clinical practice.
Treating and managing the complex etiology of myelofibrosis-associated anemia is challenging, especially for clinicians who practice outside of specialty/academic centers and do not regularly treat patients with myelofibrosis.
Learning Objective:
Upon completion of this educational activity, participants should be able to:
• Assess and apply prognostic scoring in the treatment planning process
• Select the best treatment based on patient and disease characteristics